Antihypertensive efficacy and safety of losartan/hydrochlorothiazide (HCTZ) combinations have not been adequately studied in Asians. In this open-label, 12-week study in seven Asian areas ...

For patients in the losartan 50-mg and losartan 100-mg groups, there was a non-significant decrease in FBG at 52 weeks of treatment, whereas for patients in the losartan/HCTZ 100-mg/12.5-mg ...

Adverse experiences on losartan/hydrochlorothiazide (43%) were significantly less than with the angiotensin receptor blocker alone (52.6%).

Those patients switching from losartan/HCTZ to trandolapril/verapamil experienced greater improvements in glucose and insulin response. The primary outcome measure, ...

“Patients who are taking Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP should continue taking their medication, as the risk of harm to the patient’s ...

Teva Canada is voluntarily recalling two lots of combination Losartan/hydrochlorothiazide (HCTZ) tablets after testing found that they contained levels of N-Nitroso-N-methyl-4-aminobutyric acid ...

OTTAWA, March 9, 2019 /CNW/ - Health Canada is advising Canadians that multiple lots of Losartan-containing drugs are being voluntarily recalled by Teva Canada, Apotex Inc., Pharmascience Inc ...

Losartan, a blood pressure medication in the angiotensin II receptor blocker (ARB) class, helps reduce blood pressure by preventing blood vessels from narrowing or constricting.